Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive efficacy and clean-as-whistle topline results for unpartnered RDEA594 leave some analysts predicting the drug could become a front-runner in the gout field.

You may also be interested in...



AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk

Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.

AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate

The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.

Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End

Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.

Topics

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel